Synlogic, a clinical-stage biotechnology company, has raised $42.0 million in new funding. The company is focused on advancing novel, oral, non-systemically absorbed biotherapeutics designed to transform the care of serious diseases. Its late-stage pipeline is primarily centered on rare metabolic conditions, with its lead candidate, labafenogene marselecobac (SYNB1934), currently undergoing a global, pivotal Phase 3 study, Synpheny-3, as a potential treatment for phenylketonuria (PKU).
This capital infusion is significant for Synlogic as it aims to accelerate the development of its innovative therapeutic programs. The company plans to allocate the funds towards advancing its clinical pipeline, particularly supporting the ongoing Phase 3 study for PKU, and bolstering its broader research and development initiatives. This investment underscores confidence in Synlogic's Synthetic Biotic platform and its potential to address unmet medical needs.
Synlogic's pipeline extends beyond PKU to include product candidates for diseases such as homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. These programs are fueled by the Synthetic Biotic platform, which utilizes precision genetic engineering of well-characterized probiotics. This approach enables the creation of GI-restricted, oral medicines designed to consume or modify disease-specific metabolites, making it well-suited for inborn errors of metabolism like PKU and HCU, and other disorders where disease-specific metabolites transit through the GI tract. The company also engages in research collaborations, including a partnership with Roche for inflammatory bowel disease (IBD) and a collaboration with Ginkgo Bioworks.
Looking ahead, Synlogic is poised to leverage this funding to further its mission of developing transformative treatments. The company remains committed to expanding its pipeline and bringing its Synthetic Biotic medicines to patients suffering from serious metabolic and inflammatory diseases, aiming to make a meaningful impact on patient care.
